|本期目录/Table of Contents|

[1]周楠,曹鸣芯,杨晓英.声动力联合双重免疫激活作用治疗口腔鳞状细胞癌的研究[J].天津医科大学学报,2025,31(02):167-173.
　ZHOU Nan,CAO Mingxin,YANG Xiaoying.Sonodynamic therapy combined with dual immune activation effect in the treatment of oral squamous cell carcinoma[J].Journal of Tianjin Medical University,2025,31(02):167-173.
点击复制

声动力联合双重免疫激活作用治疗口腔鳞状细胞癌的研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
31卷
期数:
2025年02期
页码:
167-173
栏目:
药学
出版日期:
2025-03-20

文章信息/Info

Title:
Sonodynamic therapy combined with dual immune activation effect in the treatment of oral squamous cell carcinoma
文章编号:
1006-8147(2025)02-0167-07
作者:
周楠1; 曹鸣芯2; 杨晓英1
（1.天津医科大学药学院药剂学系，天津300070；2.天津医科大学口腔医院正畸科，天津300070）
Author(s):
ZHOU Nan1; CAO Mingxin2; YANG Xiaoying1
（1.Department of Pharmacy，School of Pharmacy，Tianjin Medical University，Tianjin 300070，China；2.Department of Orthodontics，Stomatology Hospital，Tianjin Medical University，Tianjin 300070，China）
关键词:
口腔鳞状细胞癌; 声动力疗法; 表观遗传调控
Keywords:
oral squamous cell carcinoma; sonodynamic therapy; epigenetic regulation
分类号:
R739.8
DOI:
-
文献标志码:
A
摘要:
目的：探讨声敏剂维替泊芬（Vp）与EZH2抑制剂他泽司他（Taz）构建的纳米药物介导声动力疗法（SDT）与免疫激活协同治疗口腔鳞状细胞癌（OSCC）的作用。方法：通过将Vp与Taz共沉淀制备无载体纳米药物VpTaz，随后通过粒径电位分析仪和透射电镜检测其粒径、粒径分布和形貌特征，并采用活性氧簇（ROS）探针检测其体外SDT性能。进一步采用SCC-7细胞为OSCC细胞的研究对象，观察VpTaz被SCC-7细胞摄取的情况，检测其对胞内ROS生成和细胞毒性的作用，评估其对SCC-7细胞的杀伤性能，通过免疫荧光技术检测SCC-7细胞中高迁移率族蛋白1（HMGB1）的释放情况，考察由VpTaz的SDT作用引发的免疫原性细胞死亡（ICD）；同时，通过蛋白印迹实验考察VpTaz对H3K27me3、EZH2、Histone3蛋白表达的影响。结果：VpTaz在透射电子显微镜下呈现完整的实心球形纳米结构，水合粒径大小为（113.03±1.42） nm，分散性良好，多分散系数为0.069±0.016，且具有良好的体外SDT性能（F=1 020，P<0.001；F=27.11，P＜0.01）；其可被SCC-7细胞摄取，并在2 h达到饱和（F=802.1，P＜0.001）。在超声激发下，VpTaz处理的SCC-7细胞内产生了大量ROS（F=2 550，P<0.001），不同浓度下，非超声Vp、VpTaz组SCC-7细胞其生存率无显著性变化，Vp+US、VpTaz+US组SCC-7细胞的生存率均显著降低（F=5.463、38.53、76.74、398.7、666.7，均P＜0.05），且VpTaz可以成功促进HMGB1的释放，促进ICD的发生（F=53.1，P＜0.001）；在基因层面，对照和单纯Vp相比，Taz和VpTaz均可显著抑制主要组织相容性复合物Ⅰ类分子（MHC-Ⅰ）上游调控相关蛋白的甲基化（F=1 006，P＜0.01），并且提高MHC-Ⅰ的表达（F=3 932，P<0.001），增强SCC-7细胞免疫原性。结论：VpTaz可通过SDT杀伤和双重抗肿瘤免疫激活协同治疗OSCC。
Abstract:
Objective：To investigate the synergic effects of nanomedicine mediated sonodynamic therapy （SDT） and antitumor immune activation constructed by Verteporfin （Vp） as a sonosensitizer and Tazemetostat （Taz） as an EZH2 inhibitoron the treatment of oral squa-mous cell carcinoma （OSCC）. Methods：Carrier-free nanomedicine VpTaz was obtained by co-precipitation of Vp with Taz，followed by detecting its particle size and size distribution via a particle size potential analyser，and observation the morphological characteristics via transmission electron microscopy. The SDT performance in vitro was detected by reactive oxygen species （ROS） probes. SCC-7 cells were employedas the research object of OSCC cells. The uptake of VpTaz by SCC-7 cells was observed，its effect on intracellular ROS generation and cytotoxicity was detected. Then，the release of high mobility group protein 1 （HMGB1） in SCC-7 cells was detected by immunofluorescence technique，the immunogenic death （ICD） triggered by SDT effect of VpTaz was assessed. Meanwhile，the effect of VpTaz on the expression of H3K27me3，EZH2 and Histone3 proteins was examined by Western blotting. Results：VpTaz showed an intact solid spherical nanostructure under transmission electron microscopy，with an average hydrated particle size of （113.03±1.42） nm and well dispersed，a polydispersity coefficient of 0.069±0.016. It exhibited good SDT performance in vitro（F=1 020，P<0.001；F=27.11，P＜0.01）.VpTaz could be uptaken by SCC-7 cells and saturated at 2 h（F=802.1，P＜0.001）. Under ultrasound irradiation，SCC-7 cells treated with VpTaz exhibited higher ROS levels when compared with OSCC cells without ultrasound irradiation（F=2 550，P<0.001）. At different concentrations，there was no significant difference in the survival rate of SCC-7 cells in the non ultrasound Vp and VpTaz groups. However，the survival rate of SCC-7 cells in the Vp+US and VpTaz+US groups was significantly reduced （F=5.463，38.53，76.74， 398.7，666.7，P＜0.05，P＜0.001）. Moreover，VpTaz could facilitate the release of HMGB1 and induced ICD effect（F=53.1，P＜0.001）. On the genetic level，compared with control and Vp control，Taz and VpTaz significantly inhibited the methylation of upstream regulatory proteins related tomajor histocompatibility complex I （MHC-I）（F=1 006，P＜0.01），elevated the expression of MHC-I（F=3 932，P<0.001），and enhanced the immunogenicity of SCC-7 cells. Conclusion：VpTaz can synergistically treat OSCC through SDT killing and dual antitumor immune activation.

参考文献/References:

[1] 郑家伟，李金忠，钟来平. 口腔鳞状细胞癌临床流行病学研究现状[J]. 中国口腔颌面外科杂志，2007，5：83.
[2] 陈皓卓，郑纪伟. 口腔鳞状细胞癌治疗现状分析[J]. 徐州医科大学学报，2018，38（11）：755-757.
[3] PAN X，WANG H，WANG S，et al.Sonodynamic therapy （SDT）：a novel strategy for cancer nanotheranostics[J]. Sci China Life Sci，2018，61（4）：415-426.
[4] YAN P，LIU L H，WANG P. Sonodynamic therapy （SDT） for cancer treatment：advanced sensitizers by ultrasound activation to injury tumor[J]. ACS Appl Bio Mater，2020，3（6）：3456-3475.
[5] QIAN X，ZHENG Y，CHEN Y. Micro/nanoparticle-augmented sonodynamic therapy （SDT）：breaking the depth shallow of photoactivation[J]. Adv Mater，2016，28（37）：8097-8129.
[6] 许斌，毕良佳. 声动力疗法在口腔医学领域的研究进展[J]. 口腔疾病防治，2020，28（8）：535-539.
[7] LIANG S，YAO J，LIU D，et al. Harnessing nanomaterials for cancer sonodynamic immunotherapy[J]. Adv Mater，2023，35（33）：e2211130.
[8] ZHANG C，PU K. Organic sonodynamic materials for combination cancer immunotherapy[J]. Adv Mater，2023，35（51）：e2303059.
[9] SUN L，XU Y，ZHANG X，et al. Mesenchymal stem cells functionalized sonodynamic treatment for improving therapeutic efficacy and compliance of orthotopic oral cancer[J]. Adv Mater，2020，32（48）：e2005295.
[10] PENTER L，LIU Y，WOLFF J O，et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease[J]. Blood，2023，141（15）：1817-1830.
[11] RUI R，ZHOU L，HE S. Cancer immunotherapies：advances and bottlenecks[J]. Front Immunol，2023，14：1212476.
[12] VANDER LEUN A M，THOMMEN D S，SCHUMACHER T N. CD8+T cell states in human cancer：insights from single-cell analysis[J]. Nat Rev Cancer，2020，20（4）：218-232.
[13] NICHOLAS D，NESBITT H，FARRELL S，et al. Exploiting a rose bengal-bearing，oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancer[J]. Eur J Pharm Biopharm，2021，163：49-59.
[14] HU Z，ZHANG Q，HE Z，et al. MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy[J]. Front Immunol，2024，15：1421092.
[15] ZHOU L，MUDIANTO T，MA X，et al. Targeting EZH2 enhances antigen presentation，antitumor immunity，and circumvents anti-PD-1 resistance in head and neck cancer[J]. Clin Cancer Res，2020， 26：290-300.
[16] 李倩，王艳林. EZH2作为抗肿瘤免疫治疗靶点研究进展[J]. 生物技术通报，2015，31：29-32.
[17] 王钧，王轶楠，肖建波，等. EZH2抑制剂对恶性淋巴瘤细胞放疗抵抗、Th细胞分化及PD1/PD-L1表达的作用机制[J]. 中国老年学杂志，2024，44（4）：888-892.
[18] 朱永霞，施丽红，陈欣怡，等. 甲基转移酶EZH2在恶性肿瘤发生发展及治疗中的新进展[J]. 肿瘤预防与治疗，2021，34（10）：895-903.
[19] ZHAO L，RAO X，HUANG C，et al. Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition[J]. Biomaterials，2023，293：121952.
[20] 李健伦，黄思剑，牟漫，等. 免疫原性细胞死亡在肺癌治疗中的研究进展[J]. 华中科技大学学报（医学版），2024，53（4）：552-557.
[21] ZHOU Y，JIAO J，YANG R，et al. Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma[J]. Clin Immunol，2023，256：109772.
[22] DHATCHINAMOORTHY K，COLBERT J D，ROCK K L. Cancer immune evasion through loss of MHC class I antigen presentation[J]. Front Immunol，2021，12：636568.
[23] VIJAYAN S，SIDIQ T，YOUSUF S，et al. ClassⅠtransactivator，NLRC5：a central player in the MHC classⅠpathway and cancer immune surveillance[J]. Immunogenetics，2019，71：273-282.
[24] ZHAO M Z，SUN Y，JIANG X F，et al. Promotion on NLRC5 upregulating MHC-Ⅰexpression by IFN-γ in MHC-Ⅰ deficient breast cancer cells[J]. Immunol Res，2019，67：497-504.
[25] 刘华联，蒋敬庭. 头颈部鳞状细胞癌的肿瘤微环境及免疫治疗研究进展[J]. 中国肿瘤生物治疗杂志，2022，29（7）：671-680.

相似文献/References:

[1]张 华,杨 蓉,叶贝贝,等.389例口腔鳞状细胞癌预后影响因素分析[J].天津医科大学学报,2018,24(04):315.
　ZHANG Hua,YANG Rong,YE Bei-bei,et al.Analysis of prognostic factors for 389 patients with oral squamous cell carcinoma[J].Journal of Tianjin Medical University,2018,24(02):315.
[2]张诗晗,张健.基于TCGA数据库分析HPRT1在口腔鳞状细胞癌中的表达及意义[J].天津医科大学学报,2022,28(02):129.
　ZHANG Shi-Han,ZHANG Jian.Expression and significance of HPRT1 in oral squamous cell carcinoma based on TCGA database[J].Journal of Tianjin Medical University,2022,28(02):129.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金面上项目（12074284）
作者简介:周楠（2000-），女，硕士在读，研究方向：药剂学；通信作者：杨晓英，E-mail:yangxiaoying@tmu.edu.cn。
更新日期/Last Update: 2025-03-20